Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Lucanix™ Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy

NCT00676507 is registered in ClinicalTrials.gov with NovaRx Corporation as lead sponsor.

NCT NCT00676507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00676507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Lucanix™ Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy
Lead sponsor
NovaRx Corporation
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2008
Completion date
January 31, 2013
Enrollment
532 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma non-small cell lung cancer stage iiia, carcinoma non-small cell lung cancer stage iiib, carcinoma non-small cell lung cancer stage iv, lung neoplasm